Mobile website
Archive > Volume 24 Issue 9 > 2017,24(9):1002-1005. DOI:10.3872/j.issn.1007-385X.2017.09.013 Prev Next
Clinical Research
Expression and clinical significance of lncRNA MALAT1 in diffuse large B cell lymphoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the expression of lncRNAMALAT1 (long non-coding RNAs, metastasis-asso-ciated lung adenocarcinoma transcript 1) in the serum of DLBCL (diffuse large B-cell lymphoma) patients, and to analyze its correlation to clinical prognosis. Methods: The blood samples of 82 DLBCL patients and 32 RLH patients (lymph node reactive hyperplasia), who were diagnosed at Hematology Department of People’s Hospital of Sichuan Province from January 2010 to December 2015 with complete clinical data, were collected for this study. ln-cRNA MALAT1 expression was detected by Real-time fluorescence quantitative PCR, and the relationship between lncRNA MALAT1 expression with clinical pathological features and prognosis were analyzed. Results: Compare with RLH patients, lncRNA MALAT1 expression was significantly increased in DLBCL patients (7.48±0.27 vs 1.28±0.45, P<0.01). In addition, lncRNA MALAT1 was significantly correlated with tumor size, clinical stage, B symptoms and international prognostic index (IPI) scores. The median progression free survival time (PFS) of patients with high lncRNA MALAT1 expression was significantly shorter than those with low expression ([16.43±2.05] months vs [32.01±3.20] months, P<0.01). Cox multivariate analyses verified that lncRNA MALAT1 and IPI scores were independent predictive factors for DLBCL prognosis. Conclusion: The high expression of lncRNA MALAT1 in DLBCL patients was correlated with multiple clinicopathological parameters., and it is expected to become a new tumor marker for DLBCL prognosis.
Keywords:
Project Supported:
Project supported by the Health and Family Planning Commission of Sichuan Province （No.16PJ475）
Clc Number:
